Celgene Company Profile (NASDAQ:CELG)

About Celgene

Celgene logoCelgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CELG
  • CUSIP: 15102010
Key Metrics:
  • Previous Close: $119.25
  • 50 Day Moving Average: $116.46
  • 200 Day Moving Average: $112.01
  • 52-Week Range: $94.39 - $127.00
  • Trailing P/E Ratio: 47.89
  • Foreward P/E Ratio: 13.62
  • P/E Growth: 0.74
  • Market Cap: $92.77B
  • Outstanding Shares: 777,966,000
  • Beta: 1.74
  • Net Margins: 17.80%
  • Return on Equity: 77.95%
  • Return on Assets: 16.00%
  • Debt-to-Equity Ratio: 2.44%
  • Current Ratio: 3.61%
  • Quick Ratio: 3.42%
Additional Links:
Companies Related to Celgene:

Analyst Ratings

Consensus Ratings for Celgene (NASDAQ:CELG) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 23 Buy Ratings
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $139.71 (16.95% upside)

Analysts' Ratings History for Celgene (NASDAQ:CELG)
DateFirmActionRatingPrice TargetDetails
2/18/2017Cantor FitzgeraldSet Price TargetBuy$159.00View Rating Details
2/18/2017Credit Suisse GroupSet Price TargetBuy$148.00View Rating Details
2/18/2017J P Morgan Chase & CoReiterated RatingBuyView Rating Details
2/19/2017MizuhoSet Price TargetBuy$130.00View Rating Details
2/16/2017Canaccord GenuitySet Price TargetBuy$156.00View Rating Details
2/17/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$148.00View Rating Details
2/17/2017Robert W. BairdReiterated RatingOutperform$162.00View Rating Details
1/30/2017BTIG ResearchReiterated RatingBuy$138.00View Rating Details
1/27/2017Jefferies Group LLCBoost Price TargetBuy$142.00 -> $147.00View Rating Details
1/27/2017Barclays PLCReiterated RatingEqual Weight$120.00View Rating Details
1/27/2017Goldman Sachs Group, Inc. (The)Lower Price TargetSell$96.00 -> $91.00View Rating Details
1/27/2017Morgan StanleyLower Price TargetEqual Weight$120.00 -> $117.00View Rating Details
1/26/2017CannReiterated RatingBuyView Rating Details
1/12/2017Cowen and CompanyReiterated RatingOutperform$150.00View Rating Details
1/9/2017BMO Capital MarketsReiterated RatingBuy$144.00View Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00View Rating Details
12/4/2016RBC Capital MarketsReiterated RatingOutperformView Rating Details
11/30/2016Leerink SwannReiterated RatingMarket Perform$139.00View Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldView Rating Details
10/20/2016Stifel NicolausSet Price TargetBuy$138.00View Rating Details
10/18/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
9/29/2016Citigroup Inc.Boost Price TargetBuy$124.00 -> $127.00View Rating Details
9/16/2016Bank of America CorpReiterated RatingBuy$128.00View Rating Details
9/7/2016ArgusReiterated RatingBuy$155.00View Rating Details
7/6/2016JMP SecuritiesReiterated RatingBuy$152.00View Rating Details
5/25/2016William BlairReiterated RatingOutperformView Rating Details
4/28/2016Raymond James Financial, Inc.Reiterated RatingBuyView Rating Details
4/28/2016SunTrust Banks, Inc.Reiterated RatingBuy$145.00 -> $147.00View Rating Details
1/29/2016Royal Bank Of CanadaLower Price TargetOutperform$150.00 -> $135.00View Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingOutperformView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralView Rating Details
7/25/2015NomuraReiterated RatingBuy$165.00 -> $167.00View Rating Details
7/15/2015Deutsche Bank AGBoost Price TargetBuy$160.00 -> $175.00View Rating Details
7/2/2015Sanford C. BernsteinReiterated RatingBuy$154.00View Rating Details
(Data available from 2/23/2015 forward)


Earnings History for Celgene (NASDAQ:CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.48$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.22$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$1.06$1.07$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.99$1.01$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.95$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.89$0.90$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Celgene (NASDAQ:CELG)
Current Year EPS Consensus Estimate: $7.22 EPS
Next Year EPS Consensus Estimate: $8.77 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$1.09$1.09$1.09
Q2 20162$1.25$1.26$1.26
Q3 20163$1.28$1.31$1.30
Q4 20163$1.35$1.45$1.41
(Data provided by Zacks Investment Research)


Dividend History for Celgene (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celgene (NASDAQ:CELG)
Insider Ownership Percentage: 0.97%
Institutional Ownership Percentage: 77.68%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.00View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.56View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.00View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.40View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Celgene (NASDAQ:CELG)
nasdaq.com logoNotable ETF Outflow Detected - SSO, MDT, BA, CELG (NASDAQ:CELG)
www.nasdaq.com - February 23 at 4:13 PM
investopedia.com logoCelgene’s Revlimid Secures Label Expansion (NASDAQ:CELG)
www.investopedia.com - February 23 at 4:13 PM
us.rd.yahoo.com logo4:02 pm Celgene announces that the FDA has expanded the existing indication for REVLIMID (lenalidomide) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell tra (NASDAQ:CELG)
us.rd.yahoo.com - February 22 at 9:24 PM
News IconShares in Celgene Corporation (CELG) Acquired by Wechter Feldman Wealth Management Inc (NASDAQ:CELG)
cloudhostinghq.net - February 22 at 4:23 PM
News IconCanaccord Genuity Reiterates $156.00 Price Target for Celgene Corporation (CELG) (NASDAQ:CELG)
techknowbits.com - February 22 at 4:23 PM
News IconPfizer, Celgene, Eli Lilly, Merck & Co. CEOs and Other Execs Send Letter Supporting GOP Tax Plan - PharmaLive (press release) (subscription) (NASDAQ:CELG)
www.pharmalive.com - February 22 at 4:23 PM
finance.yahoo.com logoFDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) (NASDAQ:CELG)
finance.yahoo.com - February 22 at 4:23 PM
News IconTSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis (NASDAQ:CELG)
scienmag.com - February 22 at 12:12 PM
tmcnet.com logoActivX Biosciences, Inc. Appoints Hugh Rosen Chairman & President; John Kozarich Transitions to New Role (NASDAQ:CELG)
www.tmcnet.com - February 22 at 12:12 PM
News IconResearch Analysis of Celgene Corporation (NASDAQ:CELG) (NASDAQ:CELG)
mundoaguaysaneamiento.net - February 22 at 12:12 PM
News IconStock Price of Celgene Corporation (CELG) Increases 4.8% (NASDAQ:CELG)
prensariotiretail.com - February 22 at 12:12 PM
News IconDrilling Down Into Celgene Corporation (CELG) - StockNewsJournal (NASDAQ:CELG)
stocknewsjournal.com - February 21 at 2:11 PM
News IconOzanimod Reduces Multiple Sclerosis Relapse Rate, Phase 3 Trial Shows (NASDAQ:CELG)
multiplesclerosisnewstoday.com - February 20 at 11:53 AM
4-traders.com logoCELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Other Events (NASDAQ:CELG)
www.4-traders.com - February 20 at 11:53 AM
News IconDrilling Down Into Celgene Corp. (NASDAQ:CELG) - StockNewsJournal (NASDAQ:CELG)
stocknewsjournal.com - February 20 at 11:53 AM
fool.com logoCould Celgene Have Another Billion-Dollar Blockbuster on Its Hands? (NASDAQ:CELG)
www.fool.com - February 19 at 12:28 PM
smarteranalyst.com logoStock Update (NASDAQ:CELG): Celgene Corporation Announces Positive Phase III Results in Relapsing Multiple Sclerosis (NASDAQ:CELG)
www.smarteranalyst.com - February 18 at 9:01 AM
investors.com logoCelgene MS Drug Wins In Trial; Will Safety Top Novartis, Biogen? (NASDAQ:CELG)
www.investors.com - February 18 at 9:01 AM
News IconTaking a Look at the Chart for Celgene Corporation (CELG) - The USA Commerce (NASDAQ:CELG)
theusacommerce.com - February 17 at 3:35 PM
businesswire.com logoCelgene Announces Positive Results from Phase III SUNBEAM Trial ... - Business Wire (press release) (NASDAQ:CELG)
www.businesswire.com - February 17 at 3:35 PM
News IconStocks Quietly Mixed In Afternoon; Skyworks Breaks Out, Celgene Bases (NASDAQ:CELG)
feedproxy.google.com - February 17 at 2:54 PM
reuters.com logoBRIEF-Celgene reports positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis (NASDAQ:CELG)
www.reuters.com - February 17 at 11:37 AM
finance.yahoo.com logoAgios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up (NASDAQ:CELG)
finance.yahoo.com - February 17 at 11:37 AM
streetinsider.com logoCelgene (CELG) Phase III SUNBEAM Trial Met Primary Endpoint in MS (NASDAQ:CELG)
www.streetinsider.com - February 17 at 11:37 AM
rttnews.com logoCelgene Announces Results From Phase III SUNBEAM Trial (NASDAQ:CELG)
www.rttnews.com - February 17 at 11:37 AM
4-traders.com logoCELGENE CORP /DE/ : Other Events (form 8-K) (NASDAQ:CELG)
www.4-traders.com - February 17 at 11:37 AM
finance.yahoo.com logo7:30 am Celgene announces its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod in patients with relapsing multiple sclerosis met the primary endpoint (NASDAQ:CELG)
finance.yahoo.com - February 17 at 11:36 AM
finance.yahoo.com logoCelgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis (NASDAQ:CELG)
finance.yahoo.com - February 17 at 11:36 AM
biz.yahoo.com logoCELGENE CORP /DE/ Files SEC form 8-K, Other Events (NASDAQ:CELG)
biz.yahoo.com - February 17 at 11:36 AM
thestreet.com logoCelgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial (NASDAQ:CELG)
www.thestreet.com - February 17 at 11:36 AM
News IconInvestor Research Report on Celgene Corporation (NASDAQ:CELG) (NASDAQ:CELG)
emfizz.com - February 16 at 4:19 PM
fool.com logo3 Biotechs With Tremendously Promising Pipelines (NASDAQ:CELG)
www.fool.com - February 16 at 4:19 PM
News IconThe Research Analysts' Weekly Ratings Changes for Celgene Corporation (CELG) (NASDAQ:CELG)
fairydetox.org - February 16 at 9:20 AM
News IconAnalytical Report on Price Target: Celgene Corporation (NASDAQ:CELG) (NASDAQ:CELG)
eleganthomesinla.com - February 16 at 9:20 AM
thestreet.com logoCelgene Could Have One More Powerful Move Higher (NASDAQ:CELG)
us.rd.yahoo.com - February 16 at 9:20 AM
us.rd.yahoo.com logoCELGENE CORP /DE/ Financials (NASDAQ:CELG)
us.rd.yahoo.com - February 16 at 9:20 AM
capitalcube.com logoCelgene Corp. breached its 50 day moving average in a Bullish Manner : CELG-US : February 14, 2017 (NASDAQ:CELG)
us.rd.yahoo.com - February 14 at 4:59 PM
bizjournals.com logoSome of biotech's biggest names have acquired this Md. company (NASDAQ:CELG)
www.bizjournals.com - February 14 at 4:59 PM
bizjournals.com logoThese drug and medical device companies made the most payments to Chicago hospitals (NASDAQ:CELG)
www.bizjournals.com - February 14 at 2:55 AM
News IconTraders Alert: Gulfport Energy Corp. (NASDAQ:GPOR), Celgene Corporation (NASDAQ:CELG) - The Newburgh Press (NASDAQ:CELG)
newburghpress.com - February 13 at 4:52 PM
News IconShares of Celgene Corporation (CELG) Sees Large Inflow of Net Money Flow - Highland Mirror (NASDAQ:CELG)
www.highlandmirror.com - February 13 at 4:52 PM
us.rd.yahoo.com logoHow one stock changed my life (NASDAQ:CELG)
us.rd.yahoo.com - February 13 at 4:52 PM
us.rd.yahoo.com logoHow one stock changed my life (NASDAQ:CELG)
us.rd.yahoo.com - February 13 at 4:52 PM
fool.com logo3 Top Biotech Stocks to Buy on Sale (NASDAQ:CELG)
www.fool.com - February 13 at 11:24 AM
reuters.com logoBRIEF-Celgene receives second subpoena relating to past inquiry - SEC filing (NASDAQ:CELG)
www.reuters.com - February 10 at 4:31 PM
News IconHealthcare Companies in Hotspot: Celgene Corporation (CELG), Express Scripts Holding Company (ESRX) (NASDAQ:CELG)
xboxonezone.com - February 10 at 4:31 PM
biz.yahoo.com logoCELGENE CORP /DE/ Files SEC form 10-K, Annual Report (NASDAQ:CELG)
us.rd.yahoo.com - February 10 at 4:30 PM
News IconPPL Corporation (PPL), Celgene Corporation (CELG) Stock Eyes Ahead of Earnings - The USA Commerce (NASDAQ:CELG)
www.theusacommerce.com - February 10 at 4:30 PM
fool.com logoIs Biogen a Risky Stock? (NASDAQ:CELG)
www.fool.com - February 10 at 4:30 PM
News IconNf Trinity Capital (hong Kong) Ltd Boosts Position by $19987070 in Celgene Corporation (CELG) - Highland Mirror (NASDAQ:CELG)
www.highlandmirror.com - February 10 at 2:35 AM


What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Shares of Celgene split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

Where is Celgene's stock going? Where will Celgene's stock price be in 2017?

28 analysts have issued 12-month target prices for Celgene's shares. Their predictions range from $91.00 to $162.00. On average, they anticipate Celgene's stock price to reach $139.71 in the next year.

When will Celgene announce their earnings?

Celgene is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What are analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:

  • Robert W. Baird analysts commented, "Celgene reported positive top-line data from the SUNBEAM trial of ozanimod in multiple sclerosis. Though no numbers were provided, it looks like the primary and key secondary endpoints were met, with a similar safety profile versus the Phase 2 studies. Though we find the lack of additional safety issues encouraging, success also depends on ability to compete with Gilenya, Tecfidera, and Roche's Ocrevus on efficacy. More complete data won't be available until later this half." (2/17/2017)
  • According to Zacks Investment Research, "Celgene’s fourth quarter results were disappointing, with the company missing on both the top and the bottom line. Nevertheless, Revlimid continued to outperform in the quarter on the back of market share gains and increased duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. Both Otezla and Pomalyst achieved blockbuster status in 2016 recording over $1 billion in sales. Meanwhile, Celgene continues to progress with its label expansion efforts and pipeline development. Label expansion of approved drugs would boost its revenues. Sales of Revlimid are expected to maintain momentum along with Otezla and Pomalyst. The company’s outlook for 2017 was encouraging. Shares of Celgene have outperformed the industry in the past one year. Estimates have gone up post Q4 results. However, Celgene is highly dependent on Revlimid for growth. Stiff competition in target markets is another concern." (2/1/2017)

  • Jefferies Group LLC analysts commented, "Though updates were mostly incremental given recent pre-reporting, the review of sales dynamics, 2017 guidance, and pipeline progress reaffirms our expectation for best-in-class medium-term growth from healthy core franchises. We expect continued strong execution throughout the year and lower-risk catalysts to drive appreciation towards levels reflecting underappreciated prospects of their products and portfolio." (1/27/2017)
  • Cann analysts commented, "Celgene reported a strong quarter and year-end that was in line with expectations. The outlook for Celgene's clinical programs, based on today's update, remain very encouraging and support long-term sales and earnings growth for the company. We are modestly increasing near-term estimates, which along with a higher group PEG rate, is leading us to increase our target price to $148 from $141." (1/26/2017)
  • Cantor Fitzgerald analysts commented, "Waiting for Guidance. We expect CELG to issue guidance for 2017 in early January. Recent guidance history has involved modest guidance only to creep up through the year, which we think could occur again in 2017. We are not expecting pressure on long term guidance, and continue to value the strength of cash flow, along with share repurchases and possible upside from the pipeline. Our new 2016 forecast goes to $5.93 and our 2017 EPS forecast goes to $7.05. Revlimid Keeps on Going. A key component to CELG’s near term growth is the IMID franchise, anchored by REVLIMID and assisted by Pomalyst. The dynamics in this market (more lines of therapy, longer duration) bode well for continued growth of the multi-billion dollar franchise." (1/6/2017)

Who owns Celgene stock?

Celgene's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (4.10%), FMR LLC (2.21%), Franklin Resources Inc. (1.34%), Edgewood Management LLC (1.24%), Janus Capital Management LLC (1.10%) and Polen Capital Management LLC (0.56%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin and Thomas O Daniel.

Who sold Celgene stock? Who is selling Celgene stock?

Celgene's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Janus Capital Management LLC, Renaissance Technologies LLC, FIL Ltd, Franklin Resources Inc., Calamos Advisors LLC, Nicholas Co. Inc. WI and Eventide Asset Management LLC. Company insiders that have sold Celgene stock in the last year include Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Richard W Barker and Robert J Hugin.

Who bought Celgene stock? Who is buying Celgene stock?

Celgene's stock was purchased by a variety of institutional investors in the last quarter, including Asset Management One Co. Ltd., Polen Capital Management LLC, State Street Corp, Elkfork Partners LLC, Fred Alger Management Inc., Tyers Asset Management LLC, Russell Investments Group Ltd. and Congress Asset Management Co. MA. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Michael W Bonney.

How do I buy Celgene stock?

Shares of Celgene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Celgene stock cost?

One share of Celgene stock can currently be purchased for approximately $119.46.

Celgene (NASDAQ:CELG) Chart for Thursday, February, 23, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Earnings History Chart

Earnings by Quarter for Celgene (NASDAQ:CELG)

Dividend History Chart

Dividend Payments by Quarter for Celgene (NASDAQ:CELG)

Last Updated on 2/23/2017 by MarketBeat.com Staff